Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Sapropterin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAH known ✓ | P00439 | 1/20 | 0.62 |
| ▸ | NOS1 | P29475 | 6/20 | 0.65 |
| ▸ | CASP7 | P55210 | 2/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.65 |
| ▸ | USP2 | O75604 | 1/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.64 |
| ▸ | MAPT | P10636 | 2/20 | 0.64 |
| ▸ | BLM | P54132 | 2/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
| ▸ | GLA | P06280 | 1/20 | 0.64 |
| ▸ | HPGD | P15428 | 1/20 | 0.64 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.64 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.64 |
| ▸ | NOS3 | P29474 | 2/20 | 0.52 |
| ▸ | NOS2 | P35228 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | RGS12 | O14924 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sapropterin SCHEMBL31673726 | 1.00 | NOS1 (0.65) | NOS1CASP7HSD17B10USP2KDM4E | |
| Sapropterin SCHEMBL25915067 | 1.00 | NOS1 (0.65) | NOS1CASP7HSD17B10USP2KDM4E | |
| Sapropterin SCHEMBL20769839 | 1.00 | NOS1 (0.65) | NOS1CASP7HSD17B10USP2KDM4E | |
| Sapropterin SCHEMBL25915163 | 1.00 | NOS1 (0.65) | NOS1CASP7HSD17B10USP2KDM4E | |
| Sapropterin SCHEMBL28826011 | 1.00 | NOS1 (0.65) | NOS1CASP7HSD17B10USP2KDM4E | |
| Sapropterin SCHEMBL37480 | 1.00 | NOS1 (0.65) | NOS1CASP7HSD17B10USP2KDM4E | |
| Sapropterin SCHEMBL258544 | 1.00 | NOS1 (0.65) | NOS1CASP7HSD17B10USP2KDM4E | |
| Sapropterin SCHEMBL1650464 | 0.99 | NOS1 (0.64) | NOS1CASP7HSD17B10USP2KDM4E | |
| Sapropterin SCHEMBL21046203 | 0.99 | KDM4E (0.66) | NOS1CASP7HSD17B10USP2KDM4E | |
| Sapropterin SCHEMBL1070420 | 0.99 | KDM4E (0.66) | NOS1CASP7HSD17B10USP2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240115573-A1 | Managing the Acute and Long-Term Effects of Coronaviral Infections and Compositions Related Thereto | UNIV EMORY (US) | 2024-04-11 | — | — | US | disclosed |
| EP-4313020-A1 | MANAGING THE ACUTE AND LONG-TERM EFFECTS OF CORONAVIRAL INFECTIONS AND COMPOSITIONS RELATED THERETO | Emory University (US) | 2024-02-07 | — | — | EP | disclosed |
| WO-2023122298-A1 | PROTEIN STABILIZING COMPOUNDS CONTAINING USP28 AND/OR USP25 TARGETING LIGANDS | Stablix, Inc. (US) | 2023-06-29 | — | — | WO | disclosed |
| WO-2022272133-A2 | PROTEIN STABILIZING COMPOUNDS CONTAINING USP7 LIGANDS | Stablix, Inc. (US) | 2022-12-29 | — | — | WO | disclosed |
| WO-2022204517-A1 | MANAGING THE ACUTE AND LONG-TERM EFFECTS OF CORONAVIRAL INFECTIONS AND COMPOSITIONS RELATED THERETO | EMORY UNIVERSITY (US) | 2022-09-29 | — | — | WO | disclosed |
| CN-114814063-A | Method for detecting tetrahydrobiopterin in human body | 宁波熙宁检测技术有限公司 | 2022-07-29 | — | — | CN | disclosed |
| CN-112522222-B | Novel tryptophan hydroxylase mutant and application thereof | 河北维达康生物科技有限公司 | 2021-12-07 | — | — | CN | disclosed |
| CN-112522222-A | Novel tryptophan hydroxylase mutant and application thereof | 保定保利瑞合生物科技有限公司 | 2021-03-19 | — | — | CN | disclosed |
| US-20180221371-A1 | TREATMENT FOR THE FETUS WITH CONGENITAL HEART DISEASE | CHILDREN'S NATIONAL MEDICAL CENTER (US) | 2018-08-09 | — | — | US | disclosed |
| US-20170087157-A1 | NITRIC OXIDE-MODULATING BONE-TARGETING COMPLEXES | ELWHA LLC | 2017-03-30 | — | — | US | disclosed |
| US-20170087175-A1 | NITRIC OXIDE-MODULATING BONE-TARGETING COMPLEXES | ELWHA LLC | 2017-03-30 | — | — | US | disclosed |
| US-20170087221-A1 | NITRIC OXIDE-MODULATING BONE-TARGETING COMPLEXES | ELWHA LLC | 2017-03-30 | — | — | US | disclosed |
| US-20140309186-A1 | Metabolomics-Based Identification of Disease-Causing Agents | GEORGIA TECH RESEARCH CORPORATION | 2014-10-16 | — | — | US | disclosed |
| US-20110246081-A1 | Metabolomics-Based Identification of Disease-Causing Agents | GEORGIA TECH RESEARCH CORPORATION (US) | 2011-10-06 | — | — | US | disclosed |
| WO-2011034397-A2 | METHOD FOR PREDICTING DRUG TARGETS AND SCREENING FOR DRUGS FOR PATHOGENIC MICROORGANISMS USING ESSENTIAL METABOLITES | 한국과학기술원 (KR) | 2011-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180221371-A1 | TREATMENT FOR THE FETUS WITH CONGENITAL HEART DISEASE | HIF1AN, HIF1A, EGLN3 | PAH 17/4885NOS1 915/4885CASP7 2709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.